Abstract:BackgroundDrug-induced liver injury (DILI) is a common complication of tuberculosis treatment. We utilised data from the REMoxTB clinical trial to describe the incidence of predisposing factors and the natural history in patients with liver enzyme levels elevated in response to tuberculosis treatment.MethodsPatients received either standard tuberculosis treatment (2EHRZ/4HR), or a 4-month regimen in which moxifloxacin replaced either ethambutol (isoniazid arm, 2MHRZ/2MHR) or isoniazid (ethambutol arm, 2EMRZ/2MR). Hepatic enzymes were measured at 0, 2, 4, 8, 12 and 17 weeks and as clinically indicated during reported adverse events. Patients included were those receiving at least one dose of drug and with two or more hepatic enzyme measurements.ResultsA total of 1928 patients were included (639 2EHRZ/4HR, 654 2MHRZ/2MHR and 635 2EMRZ/2MR). DILI was defined as peak alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal (5 × ULN) or ALT ≥ 3 × ULN with total bilirubin > 2 × ULN. DILI was identified in 58 of the 1928 (3.0%) patients at a median time of 28 days (interquartile range IQR 14–56). Of 639 (6.4%) patients taking standard tuberculosis therapy, 41 experienced clinically significant enzyme elevations (peak ALT ≥ 3 × ULN). On standard therapy, 21.1% of patients aged >55 years developed a peak ALT/aspartate aminotransferase (AST) ≥ 3 × ULN (p = 0.01) and 15% of HIV-positive patients experienced a peak ALT/AST ≥ 3 × ULN compared to 9% of HIV-negative patients (p = 0.160). The median peak ALT/AST was higher in isoniazid-containing regimens vs no-isoniazid regimens (p < 0.05), and lower in moxifloxacin-containing arms vs no-moxifloxacin arms (p < 0.05). Patients receiving isoniazid reached a peak ALT ≥ 3 × ULN 9.5 days earlier than those on the ethambutol arm (median time of 28 days vs 18.5 days). Of the 67 Asian patients with a peak ALT/AST ≥ 3 × ULN, 57 (85.1%) were on an isoniazid-containing regimen (p = 0.008).ConclusionsOur results provide evidence of the risk of DILI in tuberculosis patients on standard treatment. Older patients on standard therapy, HIV-positive patients, Asian patients and those receiving isoniazid were at higher risk of elevated enzyme levels. Monitoring hepatic enzymes during the first 2 months of standard therapy detected approximately 75% of patients with a peak enzyme elevation ≥3 × ULN, suggesting this should be a standard of care. These results provide evidence for the potential of moxifloxacin in hepatic sparing.

Drug-induced liver injury in HIV-infected patients with active tuberculosis

Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis

Clinical Analysis of Antituberculosis Drug-Induced Hepatotoxicity in HIV/TB Patients

Predictive value of systemic immune-inflammatory biomarkers for drug-induced liver injury in hepatitis B virus surface antigen positive tuberculosis patients: A retrospective observational study

Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study

Incidence and risk factors of antituberculosis drug-induced liver injury in India: A systematic review and meta-analysis

Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury.

Drug-induced liver injury caused by anti-tuberculosis drugs

[Liver Injury Associated with Treatment of Multidrug-Resistant Tuberculosis: a Systematic Review and Meta-Analysis].

Impact of Antiretroviral Therapy on Anemia, Hepatotoxicity, and Immune Reconstitution Inflammatory Syndrome in HIV-Tuberculosis Co-Infected Patients

HIV–TB Coinfection: Current Therapeutic Approaches and Drug Interactions

Analysis of the relation between symptoms related to liver injuries induced by anti-tuberculosis drugs and liver injury in tuberculosis patients during treatment

Managing Hepatotoxicity Caused by Anti-tuberculosis Drugs: A Comparative Study of Approaches

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Drug-induced hepatotoxicity and association with slow acetylation variants NAT25 and NAT26 in Cameroonian patients with tuberculosis and HIV co-infection

Anti-Tuberculosis Drug-Induced Liver Injury in Shanghai: Validation of Hy’s Law

Liver Injury in HIV-1-infected Patients Receiving Non-Nucleosides Reverse Transcriptase Inhibitors-Based Antiretroviral Therapy.

Analysis on liver damage of 781 cases tuberculosis patients

Impact of adverse drug reactions on the outcomes of tuberculosis treatment

Hematological and liver toxicity of anti-tuberculosis drugs

[Systematic Review of Anti-Tuberculosis Drug Induced Adverse Reactions in China].